Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 10/2011

01-12-2011

A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation

Authors: Tom W. C. Lung, Alison J. Hayes, Andrew Hayen, Andrew Farmer, Philip M. Clarke

Published in: Quality of Life Research | Issue 10/2011

Login to get access

Abstract

Purpose

To review published studies on the effect of diabetes and its complications on utility scores to establish whether there is systematic variation across studies and to examine the implications for the estimation of quality-adjusted life years (QALYs).

Methods

A systematic review was performed using studies reporting QALY measures elicited from people with diabetes including those with a history of complications. Meta-analysis was used to obtain the average utility, and meta-regression was employed to examine the impact of study characteristics and elicitation methods on these values. The effect of different utility scores on QALYs was examined using diabetes simulation models.

Results

In the meta-analysis based on 45 studies reporting 66 values, the average utility score was 0.76 (95% CI 0.75–0.77). A meta-regression showed significant variation due to age, method of elicitation and the proportion of males. The average utility score for individual complications ranged from 0.48 (95% CI 0.25, 0.71) for chronic renal disease to 0.75 (95% CI 0.73, 0.78) for myocardial infarction, and these differences produced meaningful changes in simulated QALYs. There was significant heterogeneity between studies.

Conclusions

We provide summary utility scores for diabetes and its major complications that could help inform economic evaluation and policy analysis.
Appendix
Available only for authorised users
Literature
1.
Clarke, P. M., Gray, A. M., Briggs, A., et al. (2004). A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 68) Outcomes Model. Diabetologia, 47, 1747–1759.PubMedCrossRef
2.
Palmer, A. J., Roze, S., Valentine, W. J., et al. (2004). The CORE diabetes model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Type 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion, 20(Suppl), S5–S26.PubMedCrossRef
3.
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., et al. (2005). Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine, 142(5), 323–332.PubMed
4.
EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
5.
Horsman, J., Furlong, W., Feeny, D., & Torrance, G. (2003). The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health and Quality of Life Outcomes, 1, 54.PubMedCrossRef
6.
Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health and Quality of Life Outcomes, 1, 4.PubMedCrossRef
7.
Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal: A review. Journal of Health Economics, 5(1), 1–30.PubMedCrossRef
8.
Bharmal, M., & Thomas, J. (2006). Comparing the EQ-5D and the SF-6D Descriptive Systems to assess their ceiling effects in the US general population. Value in Health, 9(4), 262–271.PubMedCrossRef
9.
Barnett, T. E., Chumbler, N. R., Vogel, B. W., Beyth, R. J., Ryan, P., & Figueroa, S. (2007). The cost-utility of a car coordination/home telehealth programme for veterans with diabetes. Journal of Telemedicine and Telecare, 13(6), 318–321.PubMedCrossRef
10.
Douzdjian, V. (1998). Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness. American Journal of Kidney Diseases, 31(5), 794–802.PubMedCrossRef
11.
Barofsky, I., Erickson, P., & Eberhardt, M. (2004). Comparison of a single global item and an index of a multi-item health status measure among persons with and without Diabetes in the US. Quality of Life Research, 13(10), 1671–1681.PubMedCrossRef
12.
Chancellor, J., Aballea, S., Lawrence, A., Sheldon, R., Cure, S., Plun-Favreau, J., et al. (2008). Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics, 26(3), 217–234.PubMedCrossRef
13.
Maddigan, S. L., Feeny, D. G., & Johnson, J. A. (2005). Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian national population health survey. Quality of Life Research, 14(5), 1311–1320.PubMedCrossRef
14.
Sterne, J. A. C., Bradburn M. J., & Egger M. (2001) Meta-analysis in Stata. (Chapter 18) Resource document. Blackwell Publishing.
15.
Hedges, L. V., Tipton, E., & Johnson, M. C. (2010). Robust variance estimation in meta-regression with dependent effect size estimates. Research Synthesis Methods, 1(1), 39–65.CrossRef
16.
Tengs, T. O., & Lin, T. H. (2003). A Meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics, 21(3), 191–200.PubMedCrossRef
17.
Maddigan, S. L., Feeny, D. H., Johnson, J. A., & Investigators., D. O. V. E. (2004). Construct validity of the RAND-12 and Health Utilities Index Mark 2 and 3 in type 2 diabetes. Quality of Life Research, 13(2), 435–448.PubMedCrossRef
18.
Maddigan, S. L., Majumdar, S. R., Guirguis, L. M., Lewanczuk, R. Z., Lee, T. K., Toth, E. L., et al. (2004). Improvements in patient-reported outcomes associated with an intervention to enhance quality of care for rural patients with type 2 diabetes. Diabetes Care, 27(6), 1306–1312.PubMedCrossRef
19.
Boye, K. S., Matza, L. S., Oglyesby, A., Malley, K., Kim, S., Hayes, R. P. & Brodows, R. (2006). Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health and Quality of Life Outcomes, October 4, 80.
20.
Currie, C. J., Morgan, C. L., Poole, C. D., Sharplin, P., Lammert, M., & McEwan, P. (2006). Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research and Opinion, 22(8), 1523–1534.PubMedCrossRef
21.
Huang, E. S., Shook, M., Jin, L., Chin, M. H., & Meltzer, D. O. (2006). The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care, 29(2), 259–264.PubMedCrossRef
22.
Ose, D., Wensing, M., Szecsenyi, J., Joos, S., Hermann, K., & Miksch, A. (2009). Impact of primary care-based disease management on the health-related quality of life in patients with type 2 diabetes and comorbidity. Diabetes Care, 32(9), 1594–1596.PubMedCrossRef
23.
Farmer, A. J., Wade, A. N., French, D. P., Simon, J., Yudkin, P., Gray, A., et al. (2009). Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technology Assessment, 13(15), 1–50.
24.
Hammerschmidt, T., Zeitler, H. P., Gulich, M., & Leidl, R. (2004). A comparison of different strategies to collect standard gamble utilities. Medical Decision Making, 24(5), 493–503.PubMedCrossRef
25.
Shah, V. A., Gupta, S. K., Shah, K. V., Vinjamaram, S., & Chalam, K. V. (2004). TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD. Ophthalmic Epidemiology, 11(1), 43–51.PubMedCrossRef
26.
Lundkvist, J., Berne, C., Bolinder, B., & Jönsson, L. (2005). The economic and quality of life impact of hypoglycaemia. European Journal of Health Economics, 6(3), 197–202.PubMedCrossRef
27.
Wee, H. L., Li, S. C., Cheung, Y. B., Fong, K. Y., & Thumboo, J. (2006). The influence of ethnicity on health-related quality of life in diabetes mellitus: a population-based, multiethnic study. Journal of Diabetes and Its Complications, 20(3), 170–178.PubMedCrossRef
28.
Brown, S. E. S., Meltzer, D. O., Chin, M. H., & Huang, E. S. (2008). Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients. Journal of the American Geriatrics Society, 56(7), 1183–1190.PubMedCrossRef
29.
Lloyd, A., Nafees, B., Gavriel, S., Rousculp, M. D., Boye, K. S., & Ahmad, A. (2008). Health utility values associated with diabetic retinopathy. Diabetic Medicine, 25(5), 618–624.PubMedCrossRef
30.
Sakthong, P., Charoenvisuthiwongs, R., & Shabunthom, R. (2008). A comparison of EQ-5D index scores using the UK, US and Japan preference weights in a Thai sample with type 2 diabetes. Health and quality of life outcomes, 23(6), 71.CrossRef
31.
McEwen, L. N., Kim, C., Haan, M. N., Ghosh, D., Lantz, P. M., Thompson, T. J., et al. (2009). Are health-related quality-of-life and self-rated health associated with mortality? Insights from translating research into action for diabetes (TRIAD). Primary Care Diabetes, 3(1), 37–42.PubMedCrossRef
32.
ADVANCE Collaborative Group. (2007). Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 370, 829–840.CrossRef
33.
Wexler, D. J., Grant, R. W., Wittenburg, E., Bosch, J. L., Cagliero, E., Delahanty, L., et al. (2006). Correlates of health-related quality of life in Type 2 diabetes. Diabetologia, 49, 1489–1497.PubMedCrossRef
34.
Levy, A. R., Christensen, T. L., & Johnson, J. A. (2008). Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health and Quality of Life Outcomes, 29(6), 73.CrossRef
35.
Brown, M. M., Brown, G. C., Sharma, S., & Shah, G. (1999). Utility Values and Diabetic Retinopathy. American Journal of Ophthalmology, 128(3), 324–330.PubMedCrossRef
36.
Brown, G. C., Brown, M. M., Sharma, S., Brown, H., Gozum, M., & Denton, P. (2000). Quality of life associated with diabetes mellitus in an adult population. Journal of Diabetes and Its Complications, 14(1), 18–24.PubMedCrossRef
37.
Brown, M. M., Brown, G. C., Sharma, S., Landy, J., & Bakal, J. (2002). Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Archives of Ophthalmology, 120(4), 481–484.PubMed
38.
Redekop, W. K., Koopmanschap, M. A., Stolk, R. P., Rutten, G. E., Wolffenbuttel, B. H., & Niessen, L. W. (2002). Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care, 25(3), 458–463.PubMedCrossRef
39.
Sullivan, S. D., Lew, D. P., Devine, B. E., Hakim, Z., Reiber, G. E., & Veenstra, D. L. (2002). Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics, 20(15), 1079–1089.PubMedCrossRef
40.
Clarke, P., Gray, A., & Holman, R. (2002). Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Medical Decision Making, 22(4), 340–349.PubMed
41.
Hart, H. E., Bilo, H. J. G., Redekop, W. K., Stolk, R. P., Assink, J. H., & Meyboom-de Jong, B. (2003). Quality of life of patients with type 1 diabetes mellitus. Quality of Life Research, 12(8), 1089–1097.PubMedCrossRef
42.
Sharma, S., Oliver-Fernandez, A., Bakal, J., Hollands, H., Brown, G. C., & Brown, M. M. (2003). Utilities associated with diabetic retinopathy: results from a Canadian sample. The British Journal of Ophthalmology, 87(3), 259–261.PubMedCrossRef
43.
Bagust, A., & Beale, S. (2005). Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Economics, 14(3), 217–230.PubMedCrossRef
44.
Wee, H. L., Cheung, Y. B., Li, S. C., Fong, K. Y., & Thumboo, J. (2005). The impact of diabetes mellitus and other chronic medical conditions on health-related quality of life: Is the whole greater than the sum of its parts? Health and Quality of Life Outcomes January, 3, 2.CrossRef
45.
Clarke, P. M., Simon, J., Cull, C. A., & Holman, R. R. (2006). Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care, 29(7), 1506–1511.PubMedCrossRef
46.
Morgan, C. L., McEwan, P., Morrissey, M., Peters, J. R., Poole, C., & Currie, C. J. (2006). Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabetic Medicine, 23(10), 1100–1105.PubMedCrossRef
47.
Sakamaki, H., Ikeda, S., Ikegami, N., Uchigata, Y., Iwamoto, Y., Origasa, H., et al. (2006). Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value in Health, 9(1), 47–53.PubMedCrossRef
48.
Supina, A. L., Feeny, D. H., Carroll, L. J., & Johnson, J. A. (2006). Misinterpretation with norm-based scoring of health status in adults with type 1 diabetes. Health and Quality of Life Outcomes, 16(4), 15.CrossRef
49.
Boye, K. S., Yurgin, N., Dilla, T., Cordero, L. A., Badia, X., Suriñach, N. L., et al. (2007). Health-related quality of life of patients with type 2 diabetes mellitus in primary care in Spain: self-reported and proxy assessment using the EQ-5D. Journal of Medical Economics, 10(1), 41–58.CrossRef
50.
Huang, E. S., Brown, S. E., Ewigman, B. G., Foley, E. C., & Meltzer, D. O. (2007). Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care, 30(10), 2478–2483.PubMedCrossRef
51.
Glasziou, P., Alexander, J., Beller, E., Clarke, P. M., & The ADVANCE Collaborative Group. (2007). Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health and Quality of Life Outcomes, 27(5), 21.CrossRef
52.
Matza, L. S., Boye, K. S., Yurgin, N., Brewster-Jordan, J., Mannix, S., Shorr, J. M., et al. (2007). Utilities and disutilities for type 2 diabetes treatment-related attributes. Quality of Life Research, 16(7), 1251–1265.PubMedCrossRef
53.
Sullivan, P. W., Ghushchyan, V. H., & Ben-Joseph, R. (2008). The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Quality of Life Research, 17(8), 1063–1071.PubMedCrossRef
54.
Vexiau, P., Mavros, P., Krishnarajah, G., Lyu, R., & Yin, D. (2008). Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes, obesity and metabolism, 10(Suppl, 1), 16–24.PubMedCrossRef
55.
Arne, M., Janson, C., Janson, S., Boman, G., Lindqvist, U., Berne, C., et al. (2009). Physical activity and quality of life in subjects with chronic disease: Chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. Scandinavian Journal of Primary Health Care, 27(3), 141–147.PubMedCrossRef
56.
Clarke, P. M., Hayes, A. J., Glasziou, P. G., Scott, R., Simes, J., & Keech, A. C. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47(1), 61–68.PubMedCrossRef
57.
Marrett, E., Stargardt, T., Mavros, P., & Alexander, C. M. (2009). Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes, obesity and metabolism, 11(12), 1138–1144.PubMedCrossRef
58.
Zhang, X. H., Wee, H. L., Tan, K., Thumboo, J., & Li, S. C. (2009). Is diabetes knowledge associated with health-related quality of life among subjects with diabetes? A preliminary cross-sectional convenience-sampling survey study among English-speaking diabetic subjects in Singapore. Journal of Chinese Clinical medicine, 4(3), 144–150.
59.
Mills, T., Law, S. K., Walt, J., Buchholz, P., & Hansen, J. (2009). Quality of Life in Glaucoma and Three Other Chronic Diseases. Drugs and Aging, 26(11), 933–950.PubMedCrossRef
60.
Imayama, I. (2009). Determinants of quality of life in adults with diabetes. Centre of Health Promotion Studies, School of Public Health. US: DPhil University of Alberta.
61.
Cochran, J., & Conn, V. S. (2008). Meta-analysis of quality of life outcomes following diabetes self-management training. The Diabetes Educator, 34(5), 815–823.PubMedCrossRef
62.
Kind, P., Hardman, G. & Macran Susan. (1999) UK population norms for EQ-5D: Discussion Paper 172 The University of York, Centre for Health Economics.
63.
Fryback, D. G., Dunham, N. C., Palta, M., Hammer, J., Buechner, J., Cherepanov, D., et al. (2007). US Norms for six generic health-related quality of life indexes from the national health measurement study. Medical Care, 45(12), 1162–1170.PubMedCrossRef
64.
Ariza-Ariza, R., Hernandez-Cruz, B., Carmona, L., Ruiz-Montesinos, M. D., Ballina, J., Navarro-Sarabia, F., et al. (2006). Assessing utility values in rheumatoid arthritis: A comparison between time trade off and the EuroQol. Arthritis Care & Research, 55(5), 751–756.CrossRef
65.
Ramon Luengo-Fernandez. (2009). Resource costs, health outcomes and cost effectiveness in stroke care: Evidence from the Oxford Vascular Study. DPhil, Oxford University, UK.
66.
Liem, Y. S., Bosch, J. L., & Hunink, M. G. (2008). Preference-Based quality of life of patients on renal replacement therapy: A systematic review and meta-analysis. Value in Health, 11(4), 733–741.PubMedCrossRef
67.
National Institute for Clinical Excellence (NICE) (2004), Guide to the methods of technology appraisal, NICE, London.
68.
Commonwealth of Australia. (1995). Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including economic analysis. Canberra: Department of Health and Community Services.
Metadata
Title
A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation
Authors
Tom W. C. Lung
Alison J. Hayes
Andrew Hayen
Andrew Farmer
Philip M. Clarke
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Quality of Life Research / Issue 10/2011
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-011-9902-y

Other articles of this Issue 10/2011

Quality of Life Research 10/2011 Go to the issue

OriginalPaper

The perceived impact of cancer on quality of life for post-treatment survivors of childhood cancer

Brief Communication

Reliability and validity of the Taiwan (Mandarin Chinese) version of the chronic respiratory questionnaire

Erratum

Erratum to: Reliability and validity of the Taiwan (Mandarin Chinese) version of the chronic respiratory questionnaire

OriginalPaper

Impact of nocturia on disease-specific quality of life for men with localized prostate cancer

OriginalPaper

Using structural equation modeling to detect response shift in performance and health-related quality of life scores of multiple sclerosis patients

Review

Participation as an outcome measure in psychosocial oncology: content of cancer-specific health-related quality of life instruments